Literature DB >> 7518488

Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study.

I S Sheen1, Y F Liaw, D Y Lin, C M Chu.   

Abstract

Influences of hepatitis delta (HDV) or C virus (HCV) superinfection on the spontaneous clearance of hepatitis B virus (HBV) surface antigen (HBsAg) were investigated in 992 patients. Patients were infected with HBV alone (group 1), HBV and HDV (group 2), HBV and HCV (group 3), or all three viruses (group 4). They were followed for 6.2 +/- 3.7 years. Thirty-six patients (3.6%) had spontaneous serum HBsAg clearance. There was an increasing linear trend in the annual incidence from 0.43% (group 1) to 0.64% (group 2), 2.08% (group 3), and 2.33% (group 4; P < .0001). Relative risk (RR) of group 3 to 1 was 4.8 (P < .001) and of group 4 to 1 was 5.1 (P < .02). RR was significantly higher in group 3 than 2 (P < .02). By Cox multivariate regression analysis, only HCV superinfection and age at entry were significant influencing factors. Moreover, there was a significant interaction between HCV and age. Patients > 35 years old with HCV had a higher HBsAg clearance rate. Results suggest that HCV is the most important hepatotropic virus that enhances HBsAg clearance in chronic hepatitis B.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518488     DOI: 10.1093/infdis/170.2.358

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  32 in total

Review 1.  Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B.

Authors:  F V Chisari
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

2.  Hepatocellular carcinoma (HCC) recurring 10 years after clearance of hepatitis B surface antigen and 20 years after resection of hepatitis B virus-related HCC.

Authors:  Hiroji Shinkawa; Takuya Nakai; Akihiro Tamori; Hiromu Tanaka; Shigekazu Takemura; Kazuki Ohba; Takahiro Uenishi; Masao Ogawa; Satoshi Yamamoto; Seikan Hai; Tsuyoshi Ichikawa; Shintaro Kodai; Kazuhiro Hirohashi; Kenichi Wakasa; Shoji Kubo
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

Review 3.  Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues.

Authors:  Tiffany Wu; Ryan M Kwok; Tram T Tran
Journal:  Am J Gastroenterol       Date:  2017-10-31       Impact factor: 10.864

4.  Viral superinfection in previously unrecognized chronic carriers of hepatitis B virus with superimposed acute fulminant versus nonfulminant hepatitis.

Authors:  C M Chu; C T Yeh; Y F Liaw
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

Review 5.  Management of chronic hepatitis B in patients from special populations.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

6.  Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C.

Authors:  Jia-Horng Kao; Pei-Jer Chen; Ming-Yang Lai; Ding-Shinn Chen
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

7.  Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses.

Authors:  Kali Zhou; Caitlin Contag; Evans Whitaker; Norah Terrault
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-01-22

8.  Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B.

Authors:  Rong-Nan Chien
Journal:  Hepatol Int       Date:  2008-04-10       Impact factor: 6.047

9.  Spontaneous viral clearance after 6-21 years of hepatitis B and C viruses coinfection in high HBV endemic area.

Authors:  Chun-Lei Fan; Lai Wei; Dong Jiang; Hong-Song Chen; Yan Gao; Ruo-Bing Li; Yu Wang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

10.  Acute hepatitis C virus (HCV) infection in chronic carriers of hepatitis B virus (HBV): the impact of underlying active HBV replication on persistence of HCV infection and antibody responses to HCV.

Authors:  C-M Chu; C T Yeh; I S Sheen; Y F Liaw
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.